Synektik Pharma

Synektik Pharma is a specialized subsidiary of the Synektik Group, a leading provider of innovative medical solutions in Central and Eastern Europe. The company focuses on the production and distribution of radiopharmaceuticals used in PET/CT diagnostics, particularly for oncology, cardiology, and neurology. Synektik operates its own advanced Research and Development Center, where it develops proprietary radiotracers and collaborates with global pharmaceutical leaders. Beyond pharmaceuticals, the parent group is the exclusive distributor of the Da Vinci robotic surgery systems in Poland, Czech Republic, and Slovakia. The company is listed on the Warsaw Stock Exchange and is recognized for its role in advancing molecular imaging and robotic medicine. Their most significant R&D achievement is the development of flurpiridaz F 18, a cardiac imaging agent licensed to GE Healthcare.